Clovis Oncology, Inc. announces 144A offering of convertible senior notes.
On September 9, Willkie client Clovis Oncology, Inc. announced the closing of its offering of $287.5 million aggregate principal amount of its 2.50% convertible senior notes due 2021 in a Rule 144A offering to qualified institutional buyers.
Tags: Willkie Farr & Gallagher LLP







